Open AccessSwitching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
Author(s) -
Aristides K Maniatis,
Ulhas M Nadgir,
Paul Saenger,
Kent Reifschneider,
Jennifer Abuzzahab,
Larry C. Deeb,
Larry A. Fox,
Katie A. Woods,
Wenjie Song,
Meng Mao,
Steven Chessler,
Allison Komirenko,
Aimee D Shu,
Samuel J. Casella,
Paul Thornton
Publication year - 2022
Publication title -
hormone research in paediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.816
H-Index - 89
eISSN - 1663-2826
pISSN - 1663-2818
DOI - 10.1159/000524003
Subject(s) - tolerability , somatropin , medicine , adverse effect , growth hormone deficiency , pediatrics , growth hormone , hormone
The phase 3 fliGHt Trial evaluated the safety and tolerability of once-weekly lonapegsomatropin, a long-acting prodrug, in children with growth hormone deficiency (GHD) who switched from daily somatropin therapy to lonapegsomatropin.